Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Buder, A; Heitzer, E; Waldispühl-Geigl, J; Weber, S; Moser, T; Hochmair, MJ; Hackner, K; Errhalt, P; Setinek, U; Filipits, M.
Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.
BIOMOLECULES. 2021; 11(5):
Doi: 10.3390/biom11050618
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hammer Sabrina
- Heitzer Ellen
- Moser Tina
- Waldispühl-Geigl Julie
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: To assess the clinical relevance of genome-wide somatic copy-number alterations (SCNAs) in plasma circulating tumor DNA (ctDNA) from advanced epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients. METHODS: We included 43 patients with advanced EGFR T790M-positive lung adenocarcinoma who were treated with osimertinib after progression under previous EGFR-TKI therapy. We performed genomic profiling of ctDNA in plasma samples from each patient obtained pre-osimertinib and after patients developed resistance to osimertinib. SCNAs were detected by shallow whole-genome plasma sequencing and EGFR mutations were assessed by droplet digital PCR. RESULTS: SCNAs in resistance-related genes (rrSCNAs) were detected in 10 out of 31 (32%) evaluable patients before start of osimertinib. The presence of rrSCNAs in plasma before the initiation of osimertinib therapy was associated with a lower response rate to osimertinib (50% versus 81%, p = 0.08) and was an independent predictor for shorter progression-free survival (adjusted HR 3.33, 95% CI 1.37-8.10, p = 0.008) and overall survival (adjusted HR 2.54, 95% CI 1.09-5.92, p = 0.03). CONCLUSIONS: Genomic profiling of plasma ctDNA is clinically relevant and affects the efficacy and clinical outcome of osimertinib. Our approach enables the comprehensive assessment of SCNAs in plasma samples of lung adenocarcinoma patients and may help to guide genotype-specific therapeutic strategies in the future.
- Find related publications in this database (using NLM MeSH Indexing)
- Acrylamides - therapeutic use
- Adenocarcinoma - pathology
- Adenocarcinoma of Lung - genetics, metabolism, pathology
- Aged - administration & dosage
- Aged, 80 and over - administration & dosage
- Aniline Compounds - therapeutic use
- Biomarkers, Pharmacological - blood
- Carcinoma, Non-Small-Cell Lung - pathology
- Cell-Free Nucleic Acids - blood, genetics
- Circulating Tumor DNA - genetics
- DNA Copy Number Variations - genetics
- Drug Resistance, Neoplasm - genetics
- ErbB Receptors - genetics, metabolism
- Female - administration & dosage
- Humans - administration & dosage
- Liquid Biopsy - methods
- Lung - pathology
- Lung Neoplasms - genetics, pathology
- Male - administration & dosage
- Middle Aged - administration & dosage
- Progression-Free Survival - administration & dosage
- Protein Kinase Inhibitors - therapeutic use
- Find related publications in this database (Keywords)
- NSCLC
- osimertinib
- somatic copy-number alterations
- ctDNA
- EGFR mutations